The Long-Term Effects of Short-Period Adalimumab Biosimilar Usage in Ankylosing Spondylitis.

Autor:	Chopra A; Department of Rheumatology, Center for Rheumatic Diseases, Pune, IND., Khadke N; Department of Rheumatology, Center for Rheumatic Diseases, Pune, IND., Saluja M; Department of Rheumatology, Center for Rheumatic Diseases, Pune, IND., Kianifard T; Department of Rheumatology, Center for Rheumatic Diseases, Pune, IND., Venugopalan A; Department of Rheumatology, Center for Rheumatic Diseases, Pune, IND., Gharia M; Medical Content and Services, Digicare Health Solutions Private Limited, Ahmedabad, IND.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Mar 20; Vol. 15 (3), pp. e36444. Date of Electronic Publication: 2023 Mar 20 (Print Publication: 2023).
DOI:	10.7759/cureus.36444
Abstrakt:	Background Cost and drug toxicity frequently deter the long-term use of anti-tumor necrosis factor (TNF) agents in ankylosing spondylitis (AS). Therefore, this study was conducted to observe long-term relief after the short-term administration of an anti-TNF agent. Methodology A one-year, prospective, interventional, uncontrolled, single-center trial was conducted. There were 50 patients with symptomatic active chronic AS who received rheumatology therapy and were anti-TNF naive. Every two weeks, 40 mg of standard biosimilar adalimumab (Bs-ADA, Exemptia™) was administered subcutaneously for six injections (10 weeks) or to continue with standard follow-up if they did not achieve an Assessment in Ankylosing Spondylitis Response Criteria (ASAS 20) index response by week 12. Standard indicators (Assessment Spondyloarthritis International Society/ASAS and Bath) were used to evaluate progress. In addition, TNF-alpha, interleukin (IL)-6, and IL-17 were tested using a commercially available enzyme-linked immunosorbent assay kit from Bio Legend (Bengaluru, India). Results Patients experienced early and significant improvement in pain, non-steroidal anti-inflammatory drugs (NSAIDs) requirement, function, and several indices (ASAS 20 and 40, ASAS partial remission, Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Functional Index, Ankylosing Spondylitis Disease Activity Score) after discontinuing injections. At weeks 12 and 48, 84% and 52% of patients showed ASAS 20 improvement, with 34% and 24% showing ASAS partial remission. Over half of the patients continued to improve and provided proof of concept. Conclusions In difficult-to-treat AS, a 10-week course of biosimilar adalimumab demonstrated significant early improvement that often lasted for 24 weeks. This unconventional method proved to be economically appealing. It merits further confirmation and acceptance, especially in resource-constrained contexts. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Chopra et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu